Dacetuzumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Dacetuzumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CD40
Clinical data
Legal status ?
Identifiers
CAS number 880486-59-9 N
ATC code None
UNII UT59FF4T5X YesY
Synonyms SGN-40
Chemical data
Formula C6452H9964N1732O1998S42 
Mol. mass 145.1 kDa (for the peptide)
 N (what is this?)  (verify)

Dacetuzumab (also known as SGN-40 or huS2C6) is a humanized monoclonal antibody[1] being developed for the treatment of CD40-positive cancers like non-Hodgkin's lymphoma[2] and hematological malignancies.[3]

This drug was developed by Seattle Genetics, Inc.

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Dacetuzumab, American Medical Association.
  2. ^ Advani, R.; Forero-Torres, A.; Furman, R. R.; Rosenblatt, J. D.; Younes, A.; Ren, H.; Harrop, K.; Whiting, N.; Drachman, J. G. (2009). "Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma". Journal of Clinical Oncology 27 (26): 4371–4377. doi:10.1200/JCO.2008.21.3017. PMID 19636010.  edit
  3. ^ Khubchandani; Czuczman, M. S.; Hernandez-Ilizaliturri, F. J. (2009). "Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies". Current opinion in investigational drugs (London, England : 2000) 10 (6): 579–587. PMID 19513947.  edit